收费全文 | 25567篇 |
免费 | 2654篇 |
国内免费 | 821篇 |
耳鼻咽喉 | 83篇 |
儿科学 | 298篇 |
妇产科学 | 195篇 |
基础医学 | 1006篇 |
口腔科学 | 253篇 |
临床医学 | 3855篇 |
内科学 | 2345篇 |
皮肤病学 | 373篇 |
神经病学 | 1060篇 |
特种医学 | 1160篇 |
外国民族医学 | 12篇 |
外科学 | 1677篇 |
综合类 | 4927篇 |
现状与发展 | 1篇 |
一般理论 | 3篇 |
预防医学 | 1880篇 |
眼科学 | 557篇 |
药学 | 5035篇 |
101篇 | |
中国医学 | 2382篇 |
肿瘤学 | 1839篇 |
2024年 | 135篇 |
2023年 | 555篇 |
2022年 | 902篇 |
2021年 | 1354篇 |
2020年 | 1448篇 |
2019年 | 980篇 |
2018年 | 924篇 |
2017年 | 1151篇 |
2016年 | 1202篇 |
2015年 | 1096篇 |
2014年 | 2131篇 |
2013年 | 2409篇 |
2012年 | 1705篇 |
2011年 | 1560篇 |
2010年 | 1419篇 |
2009年 | 1055篇 |
2008年 | 931篇 |
2007年 | 1080篇 |
2006年 | 1008篇 |
2005年 | 933篇 |
2004年 | 761篇 |
2003年 | 650篇 |
2002年 | 525篇 |
2001年 | 544篇 |
2000年 | 440篇 |
1999年 | 336篇 |
1998年 | 303篇 |
1997年 | 201篇 |
1996年 | 160篇 |
1995年 | 144篇 |
1994年 | 134篇 |
1993年 | 128篇 |
1992年 | 120篇 |
1991年 | 150篇 |
1990年 | 89篇 |
1989年 | 59篇 |
1988年 | 51篇 |
1987年 | 28篇 |
1986年 | 40篇 |
1985年 | 36篇 |
1984年 | 35篇 |
1983年 | 18篇 |
1982年 | 15篇 |
1981年 | 20篇 |
1980年 | 25篇 |
1979年 | 20篇 |
1978年 | 11篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1974年 | 5篇 |
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献